gamma-aminobutyric acid and Acute Confusional Senile Dementia studies

gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.

Research Excerpts

Excerpt	Relevance	Reference
" In the New Drug Application for gabapentin, data from two adequate and well-controlled clinical trials was submitted to the Food and Drug Administration (FDA) in support of the approval of the indication for the treatment of post-herpetic neuralgia."	4.82	How modeling and simulation have enhanced decision making in new drug development. ( Corrigan, BW; Donevan, S; El-Kattan, A; Ewy, W; Feltner, DE; Hermann, D; Koup, JR; Kowalski, KG; Lalonde, RL; Li, CS; Lockwood, P; Miller, R; Ouellet, D; Werth, JL, 2005)
"Methylene Blue (MB) is being investigated in clinical studies for its beneficial effects in the treatment of Alzheimer disease."	3.78	Methylene blue inhibits the function of α7-nicotinic acetylcholine receptors. ( Al Mansouri, AS; Ashoor, A; Isaev, D; Keun-Hang, SY; Lorke, DE; Nurulain, SM; Oz, M; Petroianu, G, 2012)
"Synaptosomal gamma-aminobutyric acid (GABA) uptake has been used as a biochemical marker for GABAergic terminals in controls and Alzheimer disease brains."	3.67	A disorder of cortical GABAergic innervation in Alzheimer's disease. ( Barton, A; Cowburn, R; Dodd, P; Hardy, J; Lofdahl, E; O'Carroll, AM; Reynolds, G; Wester, P; Winblad, B, 1987)
"We hypothesized that restless legs syndrome (RLS), a common neurological sensorimotor disorder of uncomfortable leg sensations that appear at night and interfere with sleep, might be a cause for nighttime agitation in persons with AD."	2.94	Nighttime Agitation and Restless Legs Syndrome in Persons With Alzheimer's Disease: Study Protocol for a Double-Blind, Placebo-Controlled, Randomized Trial (NightRest). ( Allen, R; Fry, L; Gooneratne, N; Hanlon, A; Kovach, C; Loera, A; Lozano, A; Morrison, J; Rangel, A; Richards, K; Wang, YY, 2020)
"Gabapentin has been administered to several geriatric patients with bipolar disorder and patients with dementia."	2.44	Use of gabapentin in the treatment of behavioural and psychological symptoms of dementia: a review of the evidence. ( Kim, Y; Tampi, RR; Wilkins, KM, 2008)
"The key words 'dementia', 'Alzheimer's disease' and 'gabapentin' were used."	2.44	Use of gabapentin in the treatment of behavioural and psychological symptoms of dementia: a review of the evidence. ( Kim, Y; Tampi, RR; Wilkins, KM, 2008)
" Excitoxins when infused directly into the Nbm destroy non-specifically cell bodies but spare axons passing the injection site, whereas the specificity of AF64A to destroy cholinergic neurons depends on both the dosage applied and the site of injection."	2.39	Immunolesion by 192IgG-saporin of rat basal forebrain cholinergic system: a useful tool to produce cortical cholinergic dysfunction. ( Bigl, V; Rossner, S; Schliebs, R, 1996)
"Reactive astrogliosis is a hallmark of Alzheimer's disease (AD)."	1.91	Visualizing reactive astrocyte-neuron interaction in Alzheimer's disease using 11C-acetate and 18F-FDG. ( Bhalla, M; Chun, JH; Chung, JI; Han, YE; Heo, J; Hyeon, SJ; Jo, HH; Ju, YH; Kim, D; Kim, H; Kim, KJ; Kim, SY; Ko, HY; Kong, M; Kwon, J; Lee, CJ; Lee, GH; Lee, H; Lee, S; Lee, SE; Nam, MH; Oh, KT; Oh, SJ; Park, KD; Park, MA; Park, YM; Ryu, H; Stein, TD; Won, W; Yun, M, 2023)
"Interestingly, astrogliosis observed in the BFB at the pre-plaque stage was absent at the early-plaque stage."	1.72	Altered basal forebrain function during whole-brain network activity at pre- and early-plaque stages of Alzheimer's disease in TgF344-AD rats. ( Adhikari, MH; De Vos, WH; Heymans, L; Keliris, GA; Missault, S; Pintelon, I; Ponsaerts, P; Van Audekerke, J; van den Berg, M; Van der Linden, A; Vasilkovska, T; Verhoye, M; Verschuuren, M, 2022)
" Here we performed a dose-response study using fingolimod from 0."	1.51	Dual dose-dependent effects of fingolimod in a mouse model of Alzheimer's disease. ( Aytan, N; Carreras, I; Choi, JK; Dedeoglu, A; Jenkins, BG; Kowall, NW; Tognoni, CM, 2019)
"Lipid metabolism is abnormal in Alzheimer's disease (AD) brain leading to ceramide and sphingosine accumulation and reduced levels of brain sphingosine-1-phosphate (S1P)."	1.51	Dual dose-dependent effects of fingolimod in a mouse model of Alzheimer's disease. ( Aytan, N; Carreras, I; Choi, JK; Dedeoglu, A; Jenkins, BG; Kowall, NW; Tognoni, CM, 2019)
"Moreover, in mice carrying an Alzheimer's disease-related mutation in presenilin 1, astrocytes accumulated GABA even in the absence of amyloidosis."	1.48	A bell-shaped dependence between amyloidosis and GABA accumulation in astrocytes in a mouse model of Alzheimer's disease. ( Brawek, B; Chesters, R; Garaschuk, O; Hermes, M; Klement, D; Lerdkrai, C; Müller, J, 2018)
"Age and sex are risk factors of Alzheimer's disease (AD)."	1.48	Sex- and age-specific modulation of brain GABA levels in a mouse model of Alzheimer's disease. ( Alia, A; Hartlage-Rübsamen, M; Höfling, C; Matysik, J; Roy, U; Roβner, S; Stute, L, 2018)
"Sleep disorders are common in Alzheimer's disease (AD) and assumed to directly influence cognitive function and disease progression."	1.48	Intracerebroventricular streptozotocin-induced Alzheimer's disease-like sleep disorders in rats: Role of the GABAergic system in the parabrachial complex. ( Cui, SY; Cui, XY; Ding, H; Ge, YR; Hu, X; Luo, Y; Ma, YN; Shi, YT; Song, JZ; Ye, H; Zhang, YH, 2018)
"Inflammation is considered to be one of the crucial pathological factors associated with the development of Alzheimer's disease, although supportive experimental evidence remains undiscovered."	1.46	Immunological alteration & toxic molecular inductions leading to cognitive impairment & neurotoxicity in transgenic mouse model of Alzheimer's disease. ( Abdel-Rahman, E; Ahuja, M; Amin, R; Buabeid, M; Dhanasekaran, M; Majrashi, M; Parameshwaran, K; Pondugula, S; Ramesh, S; Suppiramaniam, V; Thiruchelvan, K, 2017)
"Several clinical studies have shown Alzheimer's disease to be associated with disturbances in glucose metabolism and the subsequent tricarboxylic acid (TCA) cycle-related metabolites like glutamate (Glu), glutamine (Gln), and N-acetylaspartate (NAA)."	1.40	Reversal of metabolic deficits by lipoic acid in a triple transgenic mouse model of Alzheimer's disease: a 13C NMR study. ( Cadenas, E; Díaz Brinton, R; Kanamori, K; Patil, I; Ross, BD; Sancheti, H, 2014)
"Alzheimer's disease is an age-related neurodegenerative disease characterized by deterioration of cognition and loss of memory."	1.40	Reversal of metabolic deficits by lipoic acid in a triple transgenic mouse model of Alzheimer's disease: a 13C NMR study. ( Cadenas, E; Díaz Brinton, R; Kanamori, K; Patil, I; Ross, BD; Sancheti, H, 2014)
"Amyloid-β (Aβ) plaque accumulation in Alzheimer's disease (AD) is associated with glutamatergic synapse loss, but less is known about its effect on inhibitory synapses."	1.39	Altered synapses and gliotransmission in Alzheimer's disease and AD model mice. ( Dickson, TC; Kirkcaldie, MT; Mitew, S; Vickers, JC, 2013)
" In APP/PS1 mice, a murine model of AD, at 8 months of age the cerebellum is devoid of fibrillar Aβ, but dosage of soluble Aβ(1-42), the form which is more prone to aggregation, showed higher levels in this structure than in the forebrain."	1.38	Excitability and synaptic alterations in the cerebellum of APP/PS1 mice. ( Boda, E; Hoxha, E; Montarolo, F; Parolisi, R; Tempia, F, 2012)
"Preclinical diagnosis of Alzheimer's disease is a major challenge."	1.38	Impaired glutamatergic and GABAergic function at early age in AβPPswe-PS1dE9 mice: implications for Alzheimer's disease. ( Patel, AB; Tiwari, V, 2012)
"It is known that Alzheimer's disease (AD) is a synaptic disease that involves various neurotransmitter systems, particularly those where synaptic transmission is mediated by acetylcholine or glutamate (Glu)."	1.34	Properties of glutamate receptors of Alzheimer's disease brain transplanted to frog oocytes. ( Bernareggi, A; Dueñas, Z; Miledi, R; Reyes-Ruiz, JM; Ruzzier, F, 2007)
" Chronic administration of the synthetic gonadotropin (luteinising hormone) releasing hormone analogue, goserelin, reduces testosterone activity."	1.33	Gonadotrophin-releasing hormone agonist treatment of aggression in Alzheimer's disease: a case report. ( Raskind, MA; Rosin, RA, 2005)
"At advanced stages, Alzheimer's disease (AD) is characterized by an extensive neuronal loss."	1.33	Early neuropathology of somatostatin/NPY GABAergic cells in the hippocampus of a PS1xAPP transgenic model of Alzheimer's disease. ( Baglietto-Vargas, D; Caballero, C; del Rio, JC; Gutierrez, A; Jimenez, S; Khan, ZU; Lopez-Tellez, JF; Moreno-Gonzalez, I; Ramos, B; Ruano, D; Santa-Maria, C; Vitorica, J, 2006)
"In particular, Alzheimer's disease (AD) is characterized by a selective loss of cholinergic neurons in the basal forebrain and nAChRs in particular regions controlling memory processes such as the cortex and the hippocampus."	1.33	Nicotine-induced enhancement of synaptic plasticity at CA3-CA1 synapses requires GABAergic interneurons in adult anti-NGF mice. ( Cattaneo, A; Cherubini, E; Rosato-Siri, M, 2006)
"We studied the scrapie infection of CD40L-deficient (CD40L(-/-)) mice to see whether ablation of the CD40L gene would be beneficial or detrimental in this model of a neurodegenerative amyloidosis."	1.32	Rapid disease development in scrapie-infected mice deficient for CD40 ligand. ( Baier, M; Burwinkel, M; Riemer, C; Schultz, J; Schwarz, A; van Landeghem, F, 2004)
"Furthermore, amyloid plaque size was shown to have a statistically significant effect on the relative area occupied by dystrophic glutamatergic neurites in the peri-plaque neuropile."	1.32	Structural involvement of the glutamatergic presynaptic boutons in a transgenic mouse model expressing early onset amyloid pathology. ( Bell, KF; Cuello, AC; de Kort, GJ; Ribeiro-da-Silva, A; Shigemoto, R; Steggerda, S, 2003)
"While the cholinergic depletion in Alzheimer's disease (AD) has been known for some time, a definitive involvement of other neurotransmitter systems has been somewhat more elusive."	1.32	Structural involvement of the glutamatergic presynaptic boutons in a transgenic mouse model expressing early onset amyloid pathology. ( Bell, KF; Cuello, AC; de Kort, GJ; Ribeiro-da-Silva, A; Shigemoto, R; Steggerda, S, 2003)
"Quisqualic acid was injected into the right nucleus basalis of rats."	1.31	Brain inflammatory reaction in an animal model of neuronal degeneration and its modulation by an anti-inflammatory drug: implication in Alzheimer's disease. ( Casamenti, F; Pepeu, G; Prosperi, C; Scali, C; Vannucchi, MG, 2000)
"Neurodegeneration in Alzheimer's disease is characterized by a selective loss of particular cell populations."	1.29	Cultured GABA-immunoreactive neurons are resistant to toxicity induced by beta-amyloid. ( Cotman, CW; Pike, CJ, 1993)
"Behavioural symptoms of Alzheimer's disease, such as aggression, may determine the care patients required."	1.28	Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms. ( Bowen, DM; Francis, PT; Procter, AW; Stratmann, GC, 1992)
"These observations suggest that in Alzheimer's disease there are no major changes in the extracellular concentrations of these putative amino acid transmitters."	1.27	Amino acid release from biopsy samples of temporal neocortex from patients with Alzheimer's disease. ( Bowen, DM; Davison, AN; Neary, D; Sims, NR; Smith, CC, 1983)
"Brains of 49 patients who had died with Alzheimer's disease and 54 controls were examined."	1.27	Neurochemical characteristics of early and late onset types of Alzheimer's disease. ( Iversen, LL; Mountjoy, CQ; Reynolds, GP; Rossor, MN; Roth, M, 1984)
"Both activities were reduced in Alzheimer's disease at all, although generally most extensively in the outer and middle layers of the grey matter whereas activities were near normal in the white matter."	1.27	Intralaminar neurochemical distributions in human midtemporal cortex: comparison between Alzheimer's disease and the normal. ( Atack, JR; Blessed, G; Dodd, PR; Edwardson, JA; Fairbairn, AF; Hardy, JA; Perry, EK; Perry, RH; Tomlinson, BE, 1984)
"Neuropathologically, Huntington's disease is characterized by a profound reduction in neuronal cells originating in the corpus striatum and globus pallidus."	1.26	Cerebrospinal fluid gamma-aminobutyric acid variations in neurological disorders. ( Enna, SJ; Stern, LZ; Wastek, GJ; Yamamura, HI, 1977)

Research

Studies (198)

Authors

Clinical Trials (4)

Trial Overview

Trial Outcomes

Behavioral Performance as Assessed in the Functional Magnetic Resonance Imaging (fMRI) Memory Task

Timeframe	Studies, this research(%)	All Research%
pre-1990	54 (27.27)	18.7374
1990's	19 (9.60)	18.2507
2000's	42 (21.21)	29.6817
2010's	51 (25.76)	24.3611
2020's	32 (16.16)	2.80

Authors	Studies
Hone-Blanchet, A	2
Bohsali, A	2
Krishnamurthy, LC	2
Shahid, S	1
Lin, Q	2
Zhao, L	2
Loring, D	2
Goldstein, F	2
John, SE	2
Fleischer, CC	1
Levey, A	2
Lah, J	2
Qiu, D	2
Crosson, B	2
Dou, Y	1
Xie, J	1
Tan, Y	1
Zhang, M	1
Zhao, Y	1
Liu, X	2
Czapski, GA	1
Strosznajder, JB	1
Sharma, K	1
Pradhan, S	1
Duffy, LK	1
Yeasmin, S	1
Bhattarai, N	1
Schulte, MK	1
Shabbir, U	1
Tyagi, A	1
Ham, HJ	1
Oh, DH	1
Shahid, SS	1
Bisht, AS	1
Zhu, N	1
Wei, M	1
Yuan, L	1
He, X	1
Chen, C	1
Ji, A	1
Zhang, G	1
Aranđelović, J	1
Santrač, A	1
Batinić, B	1
Todorović, L	1
Stevanović, V	1
Tiruveedhula, VVNPB	1
Sharmin, D	1
Rashid, F	1
Stanojević, B	1
Cook, JM	1
Savić, MM	1
Andersen, JV	3
Schousboe, A	3
Verkhratsky, A	2
van den Berg, M	1
Adhikari, MH	1
Verschuuren, M	1
Pintelon, I	1
Vasilkovska, T	1
Van Audekerke, J	1
Missault, S	1
Heymans, L	1
Ponsaerts, P	1
De Vos, WH	1
Van der Linden, A	1
Keliris, GA	1
Verhoye, M	1
Ali, AB	3
Islam, A	3
Constanti, A	3
Al-Kuraishy, HM	4
Al-Gareeb, AI	4
Saad, HM	3
Batiha, GE	4
Alsayegh, AA	1
Abusudah, WF	1
Almohmadi, NH	1
Eldahshan, OA	1
Ahmed, EA	1
Dilmore, AH	1
Martino, C	1
Neth, BJ	1
West, KA	1
Zemlin, J	1
Rahman, G	1
Panitchpakdi, M	1
Meehan, MJ	1
Weldon, KC	1
Blach, C	1
Schimmel, L	1
Kaddurah-Daouk, R	1
Dorrestein, PC	1
Knight, R	1
Craft, S	1
Nam, MH	2
Ko, HY	1
Kim, D	2
Lee, S	1
Park, YM	1
Hyeon, SJ	1
Won, W	1
Chung, JI	1
Kim, SY	1
Jo, HH	1
Oh, KT	1
Han, YE	1
Lee, GH	1
Ju, YH	2
Lee, H	3
Kim, H	1
Heo, J	1
Bhalla, M	1
Kim, KJ	1
Kwon, J	1
Stein, TD	1
Kong, M	1
Lee, SE	1
Oh, SJ	3
Chun, JH	1
Park, MA	1
Park, KD	2
Ryu, H	2
Yun, M	1
Lee, CJ	3
Drew, VJ	1
Park, M	3
Kim, T	2
Bäckström, T	1
Turkmen, S	1
Das, R	1
Doverskog, M	1
Blackburn, TP	1
Tambini, MD	2
Yao, W	2
D'Adamio, L	2
Cheng, A	1
Wang, J	2
Ghena, N	1
Zhao, Q	1
Perone, I	1
King, TM	1
Veech, RL	1
Gorospe, M	1
Wan, R	1
Mattson, MP	1
Wei, JP	1
Wen, W	1
Dai, Y	1
Qin, LX	1
Wen, YQ	1
Duan, DD	1
Xu, SJ	1
Yasen, AL	1
Eick, GN	1
Sterner, KN	1
Christie, AD	1
Tang, Y	1
Han, Y	1
Yu, H	1
Zhang, B	1
Li, G	1
Ciminelli, BM	1
Menduti, G	1
Benussi, L	1
Ghidoni, R	1
Binetti, G	1
Squitti, R	1
Rongioletti, M	1
Nica, S	1
Novelletto, A	1
Rossi, L	1
Malaspina, P	1
Richards, K	1
Morrison, J	1
Wang, YY	1
Rangel, A	1
Loera, A	1
Hanlon, A	1
Lozano, A	1
Kovach, C	1
Gooneratne, N	1
Fry, L	1
Allen, R	1
Fernández-Pérez, EJ	1
Gallegos, S	1
Armijo-Weingart, L	1
Araya, A	1
Riffo-Lepe, NO	1
Cayuman, F	1
Aguayo, LG	1
Busquets, O	1
Parcerisas, A	1
Verdaguer, E	1
Ettcheto, M	1
Camins, A	1
Beas-Zarate, C	1
Castro-Torres, RD	1
Auladell, C	1
Govindpani, K	3
Turner, C	1
Waldvogel, HJ	3
Faull, RLM	2
Kwakowsky, A	3
Salazar, AM	1
Leisgang, AM	1
Ortiz, AA	1
Murtishaw, AS	1
Kinney, JW	1
Christensen, SK	1
Westi, EW	1
Diaz-delCastillo, M	1
Tanila, H	1
Aldana, BI	2
Waagepetersen, HS	2
Hammoud, H	1
Netsyk, O	1
Tafreshiha, AS	1
Korol, SV	1
Jin, Z	1
Li, JP	1
Birnir, B	1
Salcedo, C	1
Wagner, A	1
Vinten, KT	1
Freude, KK	1
Araya-Arriagada, J	1
Bello, F	1
Shivashankar, G	1
Neira, D	1
Durán-Aniotz, C	1
Acosta, ML	1
Escobar, MJ	1
Hetz, C	1
Chacón, M	1
Palacios, AG	1
Holm, MM	1
Umeda, T	1
Kimura, T	1
Yoshida, K	1
Takao, K	1
Fujita, Y	1
Matsuyama, S	1
Sakai, A	1
Yamashita, M	1
Yamashita, Y	1
Ohnishi, K	1
Suzuki, M	1
Takuma, H	1
Miyakawa, T	1
Takashima, A	1
Morita, T	1
Mori, H	1
Tomiyama, T	1
Calvo-Flores Guzmán, B	2
Vinnakota, C	2
Faull, RL	1
Ahnaou, A	1
Moechars, D	1
Raeymaekers, L	1
Biermans, R	1
Manyakov, NV	1
Bottelbergs, A	1
Wintmolders, C	1
Van Kolen, K	1
Van De Casteele, T	1
Kemp, JA	2
Drinkenburg, WH	2
Brawek, B	1
Chesters, R	1
Klement, D	1
Müller, J	1
Lerdkrai, C	1
Hermes, M	1
Garaschuk, O	2
Roy, U	1
Stute, L	1
Höfling, C	1
Hartlage-Rübsamen, M	1
Matysik, J	1
Roβner, S	1
Alia, A	2
Tiwari, V	2
Saba, K	1
Veeraiah, P	1
Jose, J	1
Lakhotia, SC	1
Patel, AB	2
Hasanpour, M	1
Nourazarian, A	1
Geranmayeh, MH	1
Nikanfar, M	1
Khaki-Khatibi, F	1
Rahbarghazi, R	1
Assefa, BT	1
Gebre, AK	1
Altaye, BM	1
Cui, SY	1
Song, JZ	1
Cui, XY	1
Hu, X	1
Ma, YN	1
Shi, YT	1
Luo, Y	1
Ge, YR	1
Ding, H	1
Ye, H	1
Zhang, YH	1
Roßner, S	1
Ambrad Giovannetti, E	1
Fuhrmann, M	1
Pilipenko, V	1
Narbute, K	1
Amara, I	1
Trovato, A	1
Scuto, M	1
Pupure, J	1
Jansone, B	1
Poikans, J	1
Bisenieks, E	1
Klusa, V	1
Calabrese, V	1
Park, JH	1
Choi, JW	1
Song, HJ	1
Jang, BK	1
Woo, J	1
Chun, H	2
Kim, HJ	1
Shin, SJ	1
Yarishkin, O	2
Jo, S	2
Yeon, SK	1
Kim, S	1
Kim, J	2
Londhe, AM	1
Cho, SJ	1
Cho, S	1
Lee, C	1
Hwang, SY	1
Kim, SW	1
Cho, J	2
Pae, AN	1
Gravitz, L	1
Carreras, I	1
Aytan, N	1
Choi, JK	1
Tognoni, CM	1
Kowall, NW	2
Jenkins, BG	1
Dedeoglu, A	1
Mitew, S	1
Kirkcaldie, MT	1
Dickson, TC	1
Vickers, JC	1
Cooney, C	1
Murphy, S	1
Tessema, H	1
Freyne, A	1
Pfisterer, M	1
Govoni, S	1
Mura, E	1
Preda, S	1
Racchi, M	1
Lanni, C	1
Grilli, M	1
Zappettini, S	1
Salamone, A	1
Olivero, G	1
Pittaluga, A	1
Marchi, M	1
Sancheti, H	1
Kanamori, K	1
Patil, I	1
Díaz Brinton, R	1
Ross, BD	1
Cadenas, E	1
Nilsen, LH	2
Witter, MP	2
Sonnewald, U	2
Bai, X	1
Edden, RA	1
Gao, F	1
Wang, G	1
Wu, L	1
Zhao, B	1
Wang, M	1
Chan, Q	1
Chen, W	1
Barker, PB	1
Burbaeva, GSh	2
Boksha, IS	2
Tereshkina, EB	2
Starodubtseva, LI	1
Savushkina, OK	2
Vorob'eva, EA	1
Prokhorova, TA	2
Wu, Z	1
Guo, Z	1
Gearing, M	1
Chen, G	1
Vorobyeva, EA	1
Hwang, YJ	1
Chun, YE	1
Woo, DH	1
Bae, JY	1
Lee, J	1
Park, HJ	1
Lee, DY	1
Hong, J	1
Kim, HY	1
Park, SJ	1
Yoon, BE	1
Kim, Y	2
Jeong, Y	1
Shim, I	1
Bae, YC	1
Hwang, E	1
Laurent, C	1
Burnouf, S	1
Ferry, B	1
Batalha, VL	1
Coelho, JE	1
Baqi, Y	1
Malik, E	1
Mariciniak, E	1
Parrot, S	1
Van der Jeugd, A	1
Faivre, E	1
Flaten, V	1
Ledent, C	1
D'Hooge, R	1
Sergeant, N	1
Hamdane, M	1
Humez, S	1
Müller, CE	1
Lopes, LV	1
Buée, L	1
Blum, D	1
Kalia, M	1
Costa E Silva, J	1
Doert, A	1
Pilatus, U	1
Zanella, F	1
Müller, WE	1
Eckert, GP	1
Dulla, CG	1
Coulter, DA	1
Ziburkus, J	1
Solas, M	1
Puerta, E	1
Ramirez, MJ	2
Salminen, A	1
Jouhten, P	1
Sarajärvi, T	1
Haapasalo, A	1
Hiltunen, M	1
Khundakar, AA	1
Hanson, PS	1
Erskine, D	1
Lax, NZ	1
Roscamp, J	1
Karyka, E	1
Tsefou, E	1
Singh, P	1
Cockell, SJ	1
Gribben, A	1
Ramsay, L	1
Blain, PG	1
Mosimann, UP	1
Lett, DJ	1
Elstner, M	1
Turnbull, DM	1
Xiang, CC	1
Brownstein, MJ	1
O'Brien, JT	1
Taylor, JP	1
Attems, J	1
Thomas, AJ	1
McKeith, IG	1
Morris, CM	1
Villette, V	1
Dutar, P	1
Zhou, L	1
Ma, SL	1
Yeung, PK	1
Wong, YH	1
Tsim, KW	1
So, KF	1
Lam, LC	1
Chung, SK	1
Huang, D	1
Liu, D	1
Yin, J	1
Qian, T	1
Shrestha, S	1
Ni, H	1
Hu, B	1
Geng, C	1
Hou, XY	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease[NCT03082755]	Phase 4	156 participants (Anticipated)	Interventional	2017-07-01	Recruiting
Bridging Cognitive Aging in Rodents to Man Using fMRI in Amnestic MCI[NCT01044758]	Phase 2	96 participants (Actual)	Interventional	2009-12-31	Completed
Network-Level Mechanisms for Preclinical Alzheimer's Disease Development[NCT03461861]	Phase 2	26 participants (Actual)	Interventional	2019-04-11	Completed
Levetiracetam for Alzheimer's Disease Neuropsychiatric Symptoms Related to Epilepsy Trial (LAPSE) - A Phase II Exploratory Study[NCT04004702]	Phase 2	65 participants (Anticipated)	Interventional	2020-01-31	Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Mnemonic similarity task which assesses long term memory function. Scale ranges from 0-100 with higher scores indicating better memory performance. (NCT01044758)
Timeframe: 2 weeks

Brain Activity in the Dentate Gyrus / CA3 Subregion of the Hippocampus Measured With Blood Oxygenation Level Dependent (BOLD) Functional MRI

Intervention	percent correct recalled (Mean)
aMCI_62.5	38
aMCI_62.5 Placebo	33
aMCI_125	33
aMCI_125 Placebo	28
aMCI_250	34
aMCI_250 Placebo	31
Age Matched Control	44

Measurement of average brain activity in the dentate gyrus / CA3 subregion of the hippocampus measured with BOLD functional MRI in patients with mild cognitive impairment on placebo and on drug compared to average brain activity in this brain area in control subjects. (NCT01044758)
Timeframe: 2 weeks

Functional Connectivity Strengths of Neural Networks

Intervention	mean beta coefficient (Mean)
aMCI_62.5	-0.1203
aMCI_62.5 Placebo	0.4353
aMCI_125	-0.2238
aMCI_125 Placebo	0.8814
aMCI_250	0.3928
aMCI_250 Placebo	0.4825
Age Matched Control	-.02507

The seed-based functional connectivity strengths of the hippocampus network and the default mode network will be employed to measure the changes between AGB101 and Placebo perturbation. The functional connectivity strengths will be measured with the median of the Pearson cross-correlation coefficients over entire brain regions. (NCT03461861)
Timeframe: 2 weeks after treatment between AGB101 and Placebo

Rey Auditory Verbal Learning Test (AVLT), Delayed Recall Scaled Integer. The Higher is the Better

Intervention	Pearson coefficient (Median)
AGB101 220 mg	0.233
Placebo	0.318

Rey Auditory Verbal Learning Test (AVLT), delayed recall Scaled integer will be employed to measure the episodic memory changes before and after AGB101 treatment. The AVLT score will be recorded as a standard score. The theoretical range: min 50, max 155, the higher the better. The higher the number is, the better the memory. It is an integer number. (NCT03461861)
Timeframe: Placebo vs AGB101 2 weeks after treatment paired t-test

Reviews

49 reviews available for gamma-aminobutyric acid and Acute Confusional Senile Dementia

Trials

3 trials available for gamma-aminobutyric acid and Acute Confusional Senile Dementia

Other Studies

146 other studies available for gamma-aminobutyric acid and Acute Confusional Senile Dementia

Article	Year
Glutamate and GABA in Microglia-Neuron Cross-Talk in Alzheimer's Disease. International journal of molecular sciences, 2021, Oct-28, Volume: 22, Issue:21 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; gamma-Aminobutyric Acid; Glutamic Acid; Hu	2021
Role of Receptors in Relation to Plaques and Tangles in Alzheimer's Disease Pathology. International journal of molecular sciences, 2021, Nov-30, Volume: 22, Issue:23 Topics: Alzheimer Disease; Amyloid beta-Peptides; GABA Antagonists; gamma-Aminobutyric Acid; Humans; Neurofi	2021
Astrocyte energy and neurotransmitter metabolism in Alzheimer's disease: Integration of the glutamate/GABA-glutamine cycle. Progress in neurobiology, 2022, Volume: 217 Topics: Alzheimer Disease; Astrocytes; Energy Metabolism; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine;	2022
The fate of interneurons, GABA Brain pathology (Zurich, Switzerland), 2023, Volume: 33, Issue:1 Topics: Alzheimer Disease; Extracellular Matrix; gamma-Aminobutyric Acid; Humans; Interneurons; Receptors, G	2023
The fate of interneurons, GABA Brain pathology (Zurich, Switzerland), 2023, Volume: 33, Issue:1 Topics: Alzheimer Disease; Extracellular Matrix; gamma-Aminobutyric Acid; Humans; Interneurons; Receptors, G	2023
The fate of interneurons, GABA Brain pathology (Zurich, Switzerland), 2023, Volume: 33, Issue:1 Topics: Alzheimer Disease; Extracellular Matrix; gamma-Aminobutyric Acid; Humans; Interneurons; Receptors, G	2023
The fate of interneurons, GABA Brain pathology (Zurich, Switzerland), 2023, Volume: 33, Issue:1 Topics: Alzheimer Disease; Extracellular Matrix; gamma-Aminobutyric Acid; Humans; Interneurons; Receptors, G	2023
The fate of interneurons, GABA Brain pathology (Zurich, Switzerland), 2023, Volume: 33, Issue:1 Topics: Alzheimer Disease; Extracellular Matrix; gamma-Aminobutyric Acid; Humans; Interneurons; Receptors, G	2023
The fate of interneurons, GABA Brain pathology (Zurich, Switzerland), 2023, Volume: 33, Issue:1 Topics: Alzheimer Disease; Extracellular Matrix; gamma-Aminobutyric Acid; Humans; Interneurons; Receptors, G	2023
The fate of interneurons, GABA Brain pathology (Zurich, Switzerland), 2023, Volume: 33, Issue:1 Topics: Alzheimer Disease; Extracellular Matrix; gamma-Aminobutyric Acid; Humans; Interneurons; Receptors, G	2023
The fate of interneurons, GABA Brain pathology (Zurich, Switzerland), 2023, Volume: 33, Issue:1 Topics: Alzheimer Disease; Extracellular Matrix; gamma-Aminobutyric Acid; Humans; Interneurons; Receptors, G	2023
The fate of interneurons, GABA Brain pathology (Zurich, Switzerland), 2023, Volume: 33, Issue:1 Topics: Alzheimer Disease; Extracellular Matrix; gamma-Aminobutyric Acid; Humans; Interneurons; Receptors, G	2023
Benzodiazepines in Alzheimer's disease: beneficial or detrimental effects. Inflammopharmacology, 2023, Volume: 31, Issue:1 Topics: Aged; Alzheimer Disease; Benzodiazepines; Brain; Cognition; gamma-Aminobutyric Acid; Humans	2023
Benzodiazepines in Alzheimer's disease: beneficial or detrimental effects. Inflammopharmacology, 2023, Volume: 31, Issue:1 Topics: Aged; Alzheimer Disease; Benzodiazepines; Brain; Cognition; gamma-Aminobutyric Acid; Humans	2023
Benzodiazepines in Alzheimer's disease: beneficial or detrimental effects. Inflammopharmacology, 2023, Volume: 31, Issue:1 Topics: Aged; Alzheimer Disease; Benzodiazepines; Brain; Cognition; gamma-Aminobutyric Acid; Humans	2023
Benzodiazepines in Alzheimer's disease: beneficial or detrimental effects. Inflammopharmacology, 2023, Volume: 31, Issue:1 Topics: Aged; Alzheimer Disease; Benzodiazepines; Brain; Cognition; gamma-Aminobutyric Acid; Humans	2023
Benzodiazepines in Alzheimer's disease: beneficial or detrimental effects. Inflammopharmacology, 2023, Volume: 31, Issue:1 Topics: Aged; Alzheimer Disease; Benzodiazepines; Brain; Cognition; gamma-Aminobutyric Acid; Humans	2023
Benzodiazepines in Alzheimer's disease: beneficial or detrimental effects. Inflammopharmacology, 2023, Volume: 31, Issue:1 Topics: Aged; Alzheimer Disease; Benzodiazepines; Brain; Cognition; gamma-Aminobutyric Acid; Humans	2023
Benzodiazepines in Alzheimer's disease: beneficial or detrimental effects. Inflammopharmacology, 2023, Volume: 31, Issue:1 Topics: Aged; Alzheimer Disease; Benzodiazepines; Brain; Cognition; gamma-Aminobutyric Acid; Humans	2023
Benzodiazepines in Alzheimer's disease: beneficial or detrimental effects. Inflammopharmacology, 2023, Volume: 31, Issue:1 Topics: Aged; Alzheimer Disease; Benzodiazepines; Brain; Cognition; gamma-Aminobutyric Acid; Humans	2023
Benzodiazepines in Alzheimer's disease: beneficial or detrimental effects. Inflammopharmacology, 2023, Volume: 31, Issue:1 Topics: Aged; Alzheimer Disease; Benzodiazepines; Brain; Cognition; gamma-Aminobutyric Acid; Humans	2023
Insights on benzodiazepines' potential in Alzheimer's disease. Life sciences, 2023, May-01, Volume: 320 Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Benzodiazepines; gamma-Aminobutyric Acid; Humans; Ne	2023
The GABA system, a new target for medications against cognitive impairment-Associated with neuroactive steroids. Journal of internal medicine, 2023, Volume: 294, Issue:3 Topics: Aged; Alzheimer Disease; Animals; Cognitive Dysfunction; gamma-Aminobutyric Acid; Humans; Neurostero	2023
c-Jun N-Terminal Kinases in Alzheimer's Disease: A Possible Target for the Modulation of the Earliest Alterations. Journal of Alzheimer's disease : JAD, 2021, Volume: 82, Issue:s1 Topics: Alzheimer Disease; Animals; Brain-Derived Neurotrophic Factor; Drug Delivery Systems; gamma-Aminobut	2021
Towards a Better Understanding of GABAergic Remodeling in Alzheimer's Disease. International journal of molecular sciences, 2017, Aug-21, Volume: 18, Issue:8 Topics: Alzheimer Disease; Brain; GABAergic Neurons; gamma-Aminobutyric Acid; Humans; Neurotransmitter Agent	2017
The GABAergic system as a therapeutic target for Alzheimer's disease. Journal of neurochemistry, 2018, Volume: 146, Issue:6 Topics: Alzheimer Disease; Animals; gamma-Aminobutyric Acid; Humans; Signal Transduction	2018
The Dynamics of Neurosteroids and Sex-Related Hormones in the Pathogenesis of Alzheimer's Disease. Neuromolecular medicine, 2018, Volume: 20, Issue:2 Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Brain; Cell Differentiation; Di	2018
Reactive Astrocytes as Drug Target in Alzheimer's Disease. BioMed research international, 2018, Volume: 2018 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Aquaporin 4; Astrocytes; Calcium; Energy Metaboli	2018
Unsupervised excitation: GABAergic dysfunctions in Alzheimer's disease. Brain research, 2019, 03-15, Volume: 1707 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Disease Models, Animal; GABAergic Neurons;	2019
Dangerous liaisons between beta-amyloid and cholinergic neurotransmission. Current pharmaceutical design, 2014, Volume: 20, Issue:15 Topics: Acetylcholine; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterases; gamma-Aminobutyri	2014
Biomarkers of psychiatric diseases: current status and future prospects. Metabolism: clinical and experimental, 2015, Volume: 64, Issue:3 Suppl 1 Topics: Acetyltransferases; Alzheimer Disease; Biomarkers; Bipolar Disorder; Brain; Brain-Derived Neurotroph	2015
From Molecular Circuit Dysfunction to Disease: Case Studies in Epilepsy, Traumatic Brain Injury, and Alzheimer's Disease. The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry, 2016, Volume: 22, Issue:3 Topics: Alzheimer Disease; Animals; Brain; Brain Injuries, Traumatic; Cerebral Cortex; Epilepsy; gamma-Amino	2016
Treatment Options in Alzheimer´s Disease: The GABA Story. Current pharmaceutical design, 2015, Volume: 21, Issue:34 Topics: Aged; Alzheimer Disease; Animals; Cognition Disorders; Drug Design; gamma-Aminobutyric Acid; Humans;	2015
Hypoxia and GABA shunt activation in the pathogenesis of Alzheimer's disease. Neurochemistry international, 2016, Volume: 92 Topics: Alzheimer Disease; Animals; Butylene Glycols; Butyrates; gamma-Aminobutyric Acid; Humans; Hypoxia; S	2016
GABAergic Microcircuits in Alzheimer's Disease Models. Current Alzheimer research, 2017, Volume: 14, Issue:1 Topics: Alzheimer Disease; Animals; Disease Models, Animal; gamma-Aminobutyric Acid; Humans; Neurons	2017
Alzheimer mechanisms and therapeutic strategies. Cell, 2012, Mar-16, Volume: 148, Issue:6 Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cognition; gamma-Aminobutyric Acid; Huma	2012
GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2004, Volume: 49, Issue:7 Topics: Aged; Alzheimer Disease; Benzodiazepines; Binding Sites; Brain; Frontal Lobe; GABA Agonists; gamma-A	2004
How modeling and simulation have enhanced decision making in new drug development. Journal of pharmacokinetics and pharmacodynamics, 2005, Volume: 32, Issue:2 Topics: Alzheimer Disease; Amines; Animals; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III a	2005
Functional pharmacology in human brain. Pharmacological reviews, 2006, Volume: 58, Issue:2 Topics: Acetylcholine; Alzheimer Disease; Brain; Brain Ischemia; Epilepsy; gamma-Aminobutyric Acid; Glutamic	2006
Changes in the structural complexity of the aged brain. Aging cell, 2007, Volume: 6, Issue:3 Topics: Action Potentials; Aged; Aging; Alzheimer Disease; Brain; Dendrites; Dendritic Spines; Electrophysio	2007
Model-based drug development. Clinical pharmacology and therapeutics, 2007, Volume: 82, Issue:1 Topics: Alzheimer Disease; Amines; Analgesics; Animals; Anticholesteremic Agents; Bridged Bicyclo Compounds,	2007
GABA(A) receptors in aging and Alzheimer's disease. Journal of neurochemistry, 2007, Volume: 103, Issue:4 Topics: Aging; Alzheimer Disease; Animals; gamma-Aminobutyric Acid; Humans; Protein Subunits; Receptors, GAB	2007
Some assessments of the amygdala role in suprahypothalamic neuroendocrine regulation: a minireview. Endocrine regulations, 2007, Volume: 41, Issue:4 Topics: Alzheimer Disease; Amygdala; Anxiety Disorders; Autistic Disorder; Corticotropin-Releasing Hormone;	2007
Use of gabapentin in the treatment of behavioural and psychological symptoms of dementia: a review of the evidence. Drugs & aging, 2008, Volume: 25, Issue:3 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amines; Behavior; Cyclohexanecarboxylic Acids; Dementia,	2008
An update on the neurochemistry of Alzheimer disease. Advances in neurology, 1983, Volume: 38 Topics: Acetylcholinesterase; Alzheimer Disease; Arecoline; Brain; Choline; Choline O-Acetyltransferase; Cho	1983
Experimental pharmacology of Alzheimer disease. Advances in neurology, 1983, Volume: 38 Topics: Acetylcholine; Adult; Aged; Alzheimer Disease; Dementia; Dopamine; gamma-Aminobutyric Acid; Humans;	1983
Biological markers in mental disorders: post-mortem studies. Journal of psychiatric research, 1984, Volume: 18, Issue:4 Topics: Age Factors; Alzheimer Disease; Basal Ganglia; Brain Chemistry; Choline O-Acetyltransferase; Circadi	1984
Neurotransmitter specific alterations in dementing disorders: insights from animal models. Journal of psychiatric research, 1984, Volume: 18, Issue:4 Topics: Alzheimer Disease; Animals; Brain; Cats; Cerebral Cortex; Cholinergic Fibers; Dementia; Disease Mode	1984
Postmortem studies in psychiatry. The Psychiatric clinics of North America, 1984, Volume: 7, Issue:3 Topics: Alcoholism; Alzheimer Disease; Brain Chemistry; Cholecystokinin; Depressive Disorder; Dopamine; Endo	1984
Molecular mechanisms of associative memory and their clinical implications. Behavioural brain research, 1995, Jan-23, Volume: 66, Issue:1-2 Topics: Alzheimer Disease; Animals; Association Learning; Brain; Brain Mapping; gamma-Aminobutyric Acid; Hum	1995
Neurotransmitter replacement therapy in Alzheimer's disease. Journal of psychiatry & neuroscience : JPN, 1994, Volume: 19, Issue:1 Topics: Aged; Alzheimer Disease; Brain; Dopamine Agents; Female; gamma-Aminobutyric Acid; Humans; Male; Sero	1994
Immunolesion by 192IgG-saporin of rat basal forebrain cholinergic system: a useful tool to produce cortical cholinergic dysfunction. Progress in brain research, 1996, Volume: 109 Topics: Acetylcholine; Acetylcholinesterase; Alzheimer Disease; Animals; Antibodies, Monoclonal; Cerebral Co	1996
GABAergic deafferentation hypothesis of brain aging and Alzheimer's disease revisited. Brain research bulletin, 1998, Volume: 45, Issue:4 Topics: Aging; Alzheimer Disease; Animals; Brain; gamma-Aminobutyric Acid; Humans; Neurons, Afferent; Recept	1998
Dementia. A brief and selective review. Archives of neurology, 1976, Volume: 33, Issue:1 Topics: Alzheimer Disease; Basal Ganglia; Brain; Brain Chemistry; Caudate Nucleus; Creutzfeldt-Jakob Syndrom	1976
Biochemical approaches to dementia. Contemporary neurology series, 1977, Volume: 15 Topics: Adult; Aged; Alzheimer Disease; Animals; Brain; Cerebrovascular Circulation; Dementia; gamma-Aminobu	1977
Tacrine in relation to amino acid transmitters in Alzheimer's disease. Advances in neurology, 1990, Volume: 51 Topics: Alzheimer Disease; Aminoacridines; gamma-Aminobutyric Acid; Glutamates; Glutamic Acid; Humans; Tacri	1990
Postmortem studies of peptides in Alzheimer's disease and Huntington's disease. Research publications - Association for Research in Nervous and Mental Disease, 1986, Volume: 64 Topics: Alzheimer Disease; Basal Ganglia; Brain; Brain Chemistry; Cerebral Cortex; Choline O-Acetyltransfera	1986
Neurotransmitters in the cerebral cortex. Journal of neurosurgery, 1986, Volume: 65, Issue:2 Topics: Acetylcholine; Alzheimer Disease; Animals; Cerebral Cortex; Cerebrovascular Disorders; Dementia; Dop	1986
CSF neurotransmitter markers in Alzheimer's disease. Progress in neuro-psychopharmacology & biological psychiatry, 1986, Volume: 10, Issue:3-5 Topics: Alzheimer Disease; Biogenic Amines; Cholinesterases; gamma-Aminobutyric Acid; Humans; Neuropeptides;	1986
Cation shifts and excitotoxins in Alzheimer and Huntington disease and experimental brain damage. Progress in brain research, 1986, Volume: 70 Topics: Aged; Alzheimer Disease; Amino Acids; Animals; Brain; Brain Diseases; Calcium; Cations; gamma-Aminob	1986
[Etiopathogenesis and treatment of Alzheimer's disease]. Wiadomosci lekarskie (Warsaw, Poland : 1960), 1986, Jan-15, Volume: 39, Issue:2 Topics: Aged; Alzheimer Disease; Brain; Enzyme Activation; gamma-Aminobutyric Acid; Glutamate Decarboxylase;	1986
[Progress in the studies of the etiology and treatment of Alzheimer's disease]. Wiadomosci lekarskie (Warsaw, Poland : 1960), 1988, Jun-01, Volume: 41, Issue:11 Topics: Acetylcholine; Alzheimer Disease; Brain; Chromosome Aberrations; Chromosomes, Human, 21-22 and Y; Do	1988
Correlations between neuropathological and neurochemical changes. British medical bulletin, 1986, Volume: 42, Issue:1 Topics: Acetylcholine; Alzheimer Disease; Cerebral Cortex; gamma-Aminobutyric Acid; Humans; Nerve Tissue Pro	1986
Alzheimer's disease: a multisystem disorder. Research publications - Association for Research in Nervous and Mental Disease, 1986, Volume: 64 Topics: Alzheimer Disease; Amygdala; Animals; Brain; Catecholamines; Cerebral Cortex; Cholinergic Fibers; ga	1986
[Pathophysiology of dementia]. No to shinkei = Brain and nerve, 1985, Volume: 37, Issue:10 Topics: Acetylcholine; Aged; Aging; Alzheimer Disease; Brain; Brain Chemistry; Dementia; Dopamine; gamma-Ami	1985

Article	Year
Nighttime Agitation and Restless Legs Syndrome in Persons With Alzheimer's Disease: Study Protocol for a Double-Blind, Placebo-Controlled, Randomized Trial (NightRest). Research in gerontological nursing, 2020, 11-01, Volume: 13, Issue:6 Topics: Aged; Alzheimer Disease; Anxiety; Carbamates; Double-Blind Method; Female; gamma-Aminobutyric Acid;	2020
Gabapentin as a possible treatment of behavioral alterations in Alzheimer disease (AD) patients. European journal of neurology, 2001, Volume: 8, Issue:5 Topics: Acetates; Aged; Alzheimer Disease; Amines; Behavior; Cyclohexanecarboxylic Acids; Excitatory Amino A	2001
GABA-agonist therapy for Alzheimer's disease. Clinical neuropharmacology, 1986, Volume: 9, Issue:3 Topics: Alzheimer Disease; Clinical Trials as Topic; gamma-Aminobutyric Acid; Humans; Isoxazoles; Middle Age	1986

Article	Year
Relationships between frontal metabolites and Alzheimer's disease biomarkers in cognitively normal older adults. Neurobiology of aging, 2022, Volume: 109 Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Aspartic Acid; Biomarkers; Cognition; Creatine; Fem	2022
Neurotransmitter-stimulated neuron-derived sEVs have opposite effects on amyloid β-induced neuronal damage. Journal of nanobiotechnology, 2021, Oct-15, Volume: 19, Issue:1 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Disease Models, Animal; Extracellular Vesicles; g	2021
Comprehensive profiling of bioactive compounds in germinated black soybeans via UHPLC-ESI-QTOF-MS/MS and their anti-Alzheimer's activity. PloS one, 2022, Volume: 17, Issue:1 Topics: Alzheimer Disease; Anthocyanins; Antioxidants; Benzothiazoles; Biphenyl Compounds; Cholinesterase In	2022
Frontal Metabolites and Alzheimer's Disease Biomarkers in Healthy Older Women and Women Diagnosed with Mild Cognitive Impairment. Journal of Alzheimer's disease : JAD, 2022, Volume: 87, Issue:3 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Cognitive Dysfunction	2022
Claudin-5 relieves cognitive decline in Alzheimer's disease mice through suppression of inhibitory GABAergic neurotransmission. Aging, 2022, 04-26, Volume: 14, Issue:8 Topics: Alzheimer Disease; Animals; Claudin-5; Cognitive Dysfunction; Disease Models, Animal; gamma-Aminobut	2022
Effects of α5 GABA CNS neuroscience & therapeutics, 2022, Volume: 28, Issue:11 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Disease Models, Animal; Female; gamma-Aminobutyri	2022
Altered basal forebrain function during whole-brain network activity at pre- and early-plaque stages of Alzheimer's disease in TgF344-AD rats. Alzheimer's research & therapy, 2022, 10-10, Volume: 14, Issue:1 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Basal Forebrain; Cholinergic Agents; Disease Mode	2022
Effects of a ketogenic and low-fat diet on the human metabolome, microbiome, and foodome in adults at risk for Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2023, Volume: 19, Issue:11 Topics: Adult; Alzheimer Disease; Diet, Fat-Restricted; gamma-Aminobutyric Acid; Humans; Ketone Bodies; Meta	2023
Visualizing reactive astrocyte-neuron interaction in Alzheimer's disease using 11C-acetate and 18F-FDG. Brain : a journal of neurology, 2023, 07-03, Volume: 146, Issue:7 Topics: Alzheimer Disease; Animals; Astrocytes; Brain; Carbon Radioisotopes; Fluorodeoxyglucose F18; gamma-A	2023
GABA-Positive Astrogliosis in Sleep-Promoting Areas Associated with Sleep Disturbance in 5XFAD Mice. International journal of molecular sciences, 2023, Jun-02, Volume: 24, Issue:11 Topics: Alzheimer Disease; Animals; Electroencephalography; gamma-Aminobutyric Acid; Gliosis; Male; Mice; Sl	2023
Facilitation of glutamate, but not GABA, release in Familial Alzheimer's APP mutant Knock-in rats with increased β-cleavage of APP. Aging cell, 2019, Volume: 18, Issue:6 Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals; As	2019
SIRT3 Haploinsufficiency Aggravates Loss of GABAergic Interneurons and Neuronal Network Hyperexcitability in an Alzheimer's Disease Model. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2020, 01-15, Volume: 40, Issue:3 Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cerebral Cortex; Diet, Ketogenic; Electr	2020
Drinking water temperature affects cognitive function and progression of Alzheimer's disease in a mouse model. Acta pharmacologica Sinica, 2021, Volume: 42, Issue:1 Topics: Alzheimer Disease; Animals; Brain; Cognition; Cold Temperature; Disease Progression; Drinking Water;	2021
Motor Cortex Function in APOE4 Carriers and Noncarriers. Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society, 2021, Nov-01, Volume: 38, Issue:6 Topics: Alzheimer Disease; Apolipoprotein E4; gamma-Aminobutyric Acid; Humans; Motor Cortex; Transcranial Ma	2021
Increased GABAergic development in iPSC-derived neurons from patients with sporadic Alzheimer's disease. Neuroscience letters, 2020, 09-14, Volume: 735 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Animals; Cell Differentiation; Cell Line; Female; GABAer	2020
Polymorphic Genetic Markers of the GABA Catabolism Pathway in Alzheimer's Disease. Journal of Alzheimer's disease : JAD, 2020, Volume: 77, Issue:1 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cohort Studies; Female; gamma-Aminobutyric Acid; Genetic	2020
Changes in neuronal excitability and synaptic transmission in nucleus accumbens in a transgenic Alzheimer's disease mouse model. Scientific reports, 2020, 11-11, Volume: 10, Issue:1 Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Animals; Biomarkers; Di	2020
Impaired Expression of GABA Signaling Components in the Alzheimer's Disease Middle Temporal Gyrus. International journal of molecular sciences, 2020, Nov-18, Volume: 21, Issue:22 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Autopsy; Female; GABA Plasma Membrane Transport Proteins	2020
Alterations of GABA B receptors in the APP/PS1 mouse model of Alzheimer's disease. Neurobiology of aging, 2021, Volume: 97 Topics: Alzheimer Disease; Animals; Disease Models, Animal; gamma-Aminobutyric Acid; Glutamic Acid; Memory;	2021
Deficient astrocyte metabolism impairs glutamine synthesis and neurotransmitter homeostasis in a mouse model of Alzheimer's disease. Neurobiology of disease, 2021, Volume: 148 Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Astrocytes; Carbon Isotopes; Disease Mod	2021
Insulin differentially modulates GABA signalling in hippocampal neurons and, in an age-dependent manner, normalizes GABA-activated currents in the tg-APPSwe mouse model of Alzheimer's disease. Acta physiologica (Oxford, England), 2021, Volume: 232, Issue:2 Topics: Alzheimer Disease; Animals; gamma-Aminobutyric Acid; Hippocampus; Insulin; Mice; Neurons; Receptors,	2021
Downregulation of GABA Transporter 3 (GAT3) is Associated with Deficient Oxidative GABA Metabolism in Human Induced Pluripotent Stem Cell-Derived Astrocytes in Alzheimer's Disease. Neurochemical research, 2021, Volume: 46, Issue:10 Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Astrocytes; Down-Regulation; GABA Plasma Membrane	2021
Retinal Ganglion Cells Functional Changes in a Mouse Model of Alzheimer's Disease Are Linked with Neurotransmitter Alterations. Journal of Alzheimer's disease : JAD, 2021, Volume: 82, Issue:s1 Topics: Age Factors; Alzheimer Disease; Animals; Disease Models, Animal; Female; gamma-Aminobutyric Acid; Gl	2021
Insulin as a potent bidirectional regulator of GABAergic signalling in the hippocampus of an Alzheimer's disease mouse model. Acta physiologica (Oxford, England), 2021, Volume: 232, Issue:2 Topics: Alzheimer Disease; Animals; Disease Models, Animal; gamma-Aminobutyric Acid; Hippocampus; Insulin; M	2021
Mutation-induced loss of APP function causes GABAergic depletion in recessive familial Alzheimer's disease: analysis of Osaka mutation-knockin mice. Acta neuropathologica communications, 2017, 07-31, Volume: 5, Issue:1 Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Brain; Diazepam; Disease Models, Animal;	2017
Emergence of early alterations in network oscillations and functional connectivity in a tau seeding mouse model of Alzheimer's disease pathology. Scientific reports, 2017, 10-27, Volume: 7, Issue:1 Topics: Alzheimer Disease; Animals; Cognition; Disease Models, Animal; Electroencephalography; gamma-Aminobu	2017
A bell-shaped dependence between amyloidosis and GABA accumulation in astrocytes in a mouse model of Alzheimer's disease. Neurobiology of aging, 2018, Volume: 61 Topics: Aging; Alzheimer Disease; Amyloidogenic Proteins; Amyloidosis; Animals; Astrocytes; Brain; Disease M	2018
Sex- and age-specific modulation of brain GABA levels in a mouse model of Alzheimer's disease. Neurobiology of aging, 2018, Volume: 62 Topics: Aging; Alzheimer Disease; Amyloidogenic Proteins; Animals; Astrocytes; Brain; Disease Models, Animal	2018
Amalaki Rasayana improved memory and neuronal metabolic activity in AbPP-PS1 mouse model of Alzheimer's disease. Journal of biosciences, 2017, Volume: 42, Issue:3 Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Brain; Carbon Isotopes; Cognition; Donep	2017
Intracerebroventricular streptozotocin-induced Alzheimer's disease-like sleep disorders in rats: Role of the GABAergic system in the parabrachial complex. CNS neuroscience & therapeutics, 2018, Volume: 24, Issue:12 Topics: Alzheimer Disease; Analysis of Variance; Animals; Antibiotics, Antineoplastic; Arousal; Disease Mode	2018
Gender, GABAergic dysfunction and AD. Aging, 2018, 11-26, Volume: 10, Issue:12 Topics: Alzheimer Disease; Animals; Astrocytes; Female; gamma-Aminobutyric Acid; Hippocampus; Humans; Male;	2018
GABA-containing compound gammapyrone protects against brain impairments in Alzheimer's disease model male rats and prevents mitochondrial dysfunction in cell culture. Journal of neuroscience research, 2019, Volume: 97, Issue:6 Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Astrocytes; Brain; Cells, Cultured; Disease Models	2019
GABAergic astrocytes in Alzheimer's disease. Aging, 2019, 03-15, Volume: 11, Issue:6 Topics: Alzheimer Disease; Animals; Astrocytes; gamma-Aminobutyric Acid; Humans; Mice	2019
Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer's disease. Science advances, 2019, Volume: 5, Issue:3 Topics: Alzheimer Disease; Animals; Astrocytes; Cognitive Dysfunction; D-Amino-Acid Oxidase; Enzyme Inhibito	2019
Tuning of Glutamate, But Not GABA, Release by an Intrasynaptic Vesicle APP Domain Whose Function Can Be Modulated by β- or α-Secretase Cleavage. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2019, 08-28, Volume: 39, Issue:35 Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals; Fe	2019
The forgotten part of memory. Nature, 2019, Volume: 571, Issue:7766 Topics: Alzheimer Disease; Animals; Anxiety; Brain; Cerebral Cortex; Dopamine; Dopaminergic Neurons; Drosoph	2019
Dual dose-dependent effects of fingolimod in a mouse model of Alzheimer's disease. Scientific reports, 2019, 07-29, Volume: 9, Issue:1 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Astrocytes; Brain; Disease Models, Animal; Drug R	2019
Altered synapses and gliotransmission in Alzheimer's disease and AD model mice. Neurobiology of aging, 2013, Volume: 34, Issue:10 Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Animals; Astrocytes; Cerebral Cortex; Disease Model	2013
Use of low-dose gabapentin for aggressive behavior in vascular and Mixed Vascular/Alzheimer Dementia. The Journal of neuropsychiatry and clinical neurosciences, 2013,Spring, Volume: 25, Issue:2 Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Amines; Cyclohexanecarboxylic Acids; Dementi	2013
[Palliative care in geriatrics]. Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138, Issue:23 Topics: Alzheimer Disease; Analgesics; Cooperative Behavior; gamma-Aminobutyric Acid; Geriatrics; Germany; H	2013
Reversal of metabolic deficits by lipoic acid in a triple transgenic mouse model of Alzheimer's disease: a 13C NMR study. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2014, Volume: 34, Issue:2 Topics: Alzheimer Disease; Animals; Aspartic Acid; Biomarkers; Citric Acid Cycle; gamma-Aminobutyric Acid; G	2014
Neuronal and astrocytic metabolism in a transgenic rat model of Alzheimer's disease. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2014, Volume: 34, Issue:5 Topics: Alzheimer Disease; Animals; Astrocytes; Brain; Citric Acid Cycle; Disease Models, Animal; Female; ga	2014
Decreased γ-aminobutyric acid levels in the parietal region of patients with Alzheimer's disease. Journal of magnetic resonance imaging : JMRI, 2015, Volume: 41, Issue:5 Topics: Aged; Alzheimer Disease; Biomarkers; Down-Regulation; Female; Frontal Lobe; gamma-Aminobutyric Acid;	2015
[A role of glutamate decarboxylase in Alzheimer's disease]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2014, Volume: 114, Issue:4 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebellum; Female; gamma-Aminobutyric Acid; Glutamate D	2014
Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzheimer's [corrected] disease model. Nature communications, 2014, Jun-13, Volume: 5 Topics: Alzheimer Disease; Animals; Astrocytes; Dentate Gyrus; Disease Models, Animal; Female; gamma-Aminobu	2014
Glutamate and GABA-metabolizing enzymes in post-mortem cerebellum in Alzheimer's disease: phosphate-activated glutaminase and glutamic acid decarboxylase. Cerebellum (London, England), 2014, Volume: 13, Issue:5 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amide Synthases; Cerebellum; gamma-Aminobutyric Acid; Gl	2014
GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease. Nature medicine, 2014, Volume: 20, Issue:8 Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Astrocytes;	2014
A2A adenosine receptor deletion is protective in a mouse model of Tauopathy. Molecular psychiatry, 2016, Volume: 21, Issue:1 Topics: Adenosine A2 Receptor Antagonists; Alzheimer Disease; Animals; Cognition Disorders; Disease Models,	2016
¹H- and ¹³C-NMR spectroscopy of Thy-1-APPSL mice brain extracts indicates metabolic changes in Alzheimer's disease. Journal of neural transmission (Vienna, Austria : 1996), 2015, Volume: 122, Issue:4 Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Br	2015
Analysis of primary visual cortex in dementia with Lewy bodies indicates GABAergic involvement associated with recurrent complex visual hallucinations. Acta neuropathologica communications, 2016, 06-30, Volume: 4, Issue:1 Topics: alpha-Synuclein; Alzheimer Disease; Amyloid beta-Peptides; Enzyme-Linked Immunosorbent Assay; gamma-	2016
Anxiety and depression with neurogenesis defects in exchange protein directly activated by cAMP 2-deficient mice are ameliorated by a selective serotonin reuptake inhibitor, Prozac. Translational psychiatry, 2016, 09-06, Volume: 6, Issue:9 Topics: Affect; Aged; Aged, 80 and over; Alzheimer Disease; Animals; Anxiety; Asian People; Behavior, Animal	2016
Glutamate-glutamine and GABA in brain of normal aged and patients with cognitive impairment. European radiology, 2017, Volume: 27, Issue:7 Topics: Adult; Aged; Aging; Alzheimer Disease; Analysis of Variance; Case-Control Studies; Cognitive Dysfunc	2017
Oligomeric amyloid-β peptide disrupts olfactory information output by impairment of local inhibitory circuits in rat olfactory bulb. Neurobiology of aging, 2017, Volume: 51 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; gamma-Aminobutyric Acid; Inhibitory Postsynaptic	2017
Age-dependent concomitant changes in synaptic dysfunction and GABAergic pathway in the APP/PS1 mouse model. Acta neurobiologiae experimentalis, 2016, Volume: 76, Issue:4 Topics: Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Disease Models, Animal; Dose-Resp	2016
Optogenetic Restoration of Disrupted Slow Oscillations Halts Amyloid Deposition and Restores Calcium Homeostasis in an Animal Model of Alzheimer's Disease. PloS one, 2017, Volume: 12, Issue:1 Topics: Alzheimer Disease; Amyloid; Animals; Calcium; Disease Models, Animal; Down-Regulation; gamma-Aminobu	2017
Immunological alteration & toxic molecular inductions leading to cognitive impairment & neurotoxicity in transgenic mouse model of Alzheimer's disease. Life sciences, 2017, May-15, Volume: 177 Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Cognition D	2017
[Restless legs syndrome in the elderly: an unrecognized disorder]. Revue medicale suisse, 2008, Nov-05, Volume: 4, Issue:178 Topics: Aged, 80 and over; Alzheimer Disease; Amines; Anticonvulsants; Benzodiazepines; Cyclohexanecarboxyli	2008
GABAergic drugs and Alzheimer's disease. Future medicinal chemistry, 2011, Volume: 3, Issue:2 Topics: Alzheimer Disease; Animals; Brain; gamma-Aminobutyric Acid; Humans; Pharmaceutical Preparations; Rec	2011
Impaired glutamatergic and GABAergic function at early age in AβPPswe-PS1dE9 mice: implications for Alzheimer's disease. Journal of Alzheimer's disease : JAD, 2012, Volume: 28, Issue:4 Topics: Age Factors; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Disease Models, Animal; gam	2012
Methylene blue inhibits the function of α7-nicotinic acetylcholine receptors. CNS & neurological disorders drug targets, 2012, Volume: 11, Issue:6 Topics: alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Animals; Bungarotoxins; CA1 Region, Hipp	2012
Excitability and synaptic alterations in the cerebellum of APP/PS1 mice. PloS one, 2012, Volume: 7, Issue:4 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cerebellum; Disease Models, Animal; gamma-Aminobu	2012
Altered neurochemical profile in the McGill-R-Thy1-APP rat model of Alzheimer's disease: a longitudinal in vivo 1 H MRS study. Journal of neurochemistry, 2012, Volume: 123, Issue:4 Topics: Age Factors; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Choline; Cre	2012
Alzheimer's disease: amino acid levels and brain metabolic status. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2013, Volume: 34, Issue:9 Topics: Aged; Alzheimer Disease; Amino Acids; Brain; Chromatography, High Pressure Liquid; Female; gamma-Ami	2013
Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an Abeta-like peptide. The Journal of biological chemistry, 2002, Nov-22, Volume: 277, Issue:47 Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amylo	2002
Long-term potentiation is increased in the CA1 area of the hippocampus of APP(swe/ind) CRND8 mice. Neurobiology of disease, 2002, Volume: 11, Issue:3 Topics: Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Disease Models, Animal; Electroph	2002
Impaired modulation of GABAergic transmission by muscarinic receptors in a mouse transgenic model of Alzheimer's disease. The Journal of biological chemistry, 2003, Jul-18, Volume: 278, Issue:29 Topics: Action Potentials; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Carbachol; Disease Mo	2003
SDF-1alpha is expressed in astrocytes and neurons in the AIDS dementia complex: an in vivo and in vitro study. Journal of neuropathology and experimental neurology, 2003, Volume: 62, Issue:6 Topics: AIDS Dementia Complex; Alzheimer Disease; Animals; Astrocytes; Basal Ganglia; Blotting, Northern; Bl	2003
Structural involvement of the glutamatergic presynaptic boutons in a transgenic mouse model expressing early onset amyloid pathology. Neuroscience letters, 2003, Dec-19, Volume: 353, Issue:2 Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cerebral Cortex;	2003
Motor cortex hyperexcitability to transcranial magnetic stimulation in Alzheimer's disease. Journal of neurology, neurosurgery, and psychiatry, 2004, Volume: 75, Issue:4 Topics: Afferent Pathways; Aged; Alzheimer Disease; Carbamates; Cerebral Cortex; Cholinergic Fibers; Choline	2004
Rapid disease development in scrapie-infected mice deficient for CD40 ligand. EMBO reports, 2004, Volume: 5, Issue:5 Topics: Alzheimer Disease; Animals; Biomarkers; Brain; CD40 Antigens; CD40 Ligand; Disease Progression; Fema	2004
Can gabapentin be a safe alternative to hormonal therapy in the treatment of inappropriate sexual behavior in demented patients? International urology and nephrology, 2003, Volume: 35, Issue:2 Topics: Acetates; Aged; Alzheimer Disease; Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyr	2003
Gabapentin and behavioral disorders in severe Alzheimer disease. Journal of clinical psychopharmacology, 2004, Volume: 24, Issue:4 Topics: Acetates; Aged; Aged, 80 and over; Alzheimer Disease; Amines; Cyclohexanecarboxylic Acids; Female; F	2004
Synaptic transmission and synchronous activity is disrupted in hippocampal slices taken from aged TAS10 mice. Hippocampus, 2005, Volume: 15, Issue:1 Topics: 4-Aminopyridine; Action Potentials; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cort	2005
Pouring oil into the fire? On the conundrum of the beneficial effects of NMDA receptor antagonists in Alzheimer disease. Psychopharmacology, 2005, Volume: 179, Issue:1 Topics: Alzheimer Disease; Calcium; Excitatory Amino Acid Antagonists; gamma-Aminobutyric Acid; Humans; Rece	2005
Involvement of the GABAergic system in depressive symptoms of Alzheimer's disease. Neurobiology of aging, 2006, Volume: 27, Issue:8 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebral Cortex; Cognition Disorders; Depression; Female	2006
Gonadotrophin-releasing hormone agonist treatment of aggression in Alzheimer's disease: a case report. International psychogeriatrics, 2005, Volume: 17, Issue:2 Topics: Aged; Aggression; Alzheimer Disease; Amines; Antipsychotic Agents; Benzodiazepines; Cyclohexanecarbo	2005
Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2005, Sep-28, Volume: 25, Issue:39 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aging; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-P	2005
Early neuropathology of somatostatin/NPY GABAergic cells in the hippocampus of a PS1xAPP transgenic model of Alzheimer's disease. Neurobiology of aging, 2006, Volume: 27, Issue:11 Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Blotting, Western; gamma-Aminobutyric Ac	2006
The amyloid pathology progresses in a neurotransmitter-specific manner. Neurobiology of aging, 2006, Volume: 27, Issue:11 Topics: Acetylcholine; Aged; Aged, 80 and over; Alzheimer Disease; Animals; Blotting, Western; Brain; Female	2006
Synapse formation and function is modulated by the amyloid precursor protein. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2006, Jul-05, Volume: 26, Issue:27 Topics: Action Potentials; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid	2006
Behavioral correlates of GABAergic disruption in Alzheimer's disease. International psychogeriatrics, 2007, Volume: 19, Issue:1 Topics: Affect; Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Cognition Disorders; Depressive Diso	2007
Nicotine-induced enhancement of synaptic plasticity at CA3-CA1 synapses requires GABAergic interneurons in adult anti-NGF mice. The Journal of physiology, 2006, Oct-15, Volume: 576, Issue:Pt 2 Topics: Alzheimer Disease; Animals; Disease Models, Animal; Excitatory Postsynaptic Potentials; Female; gamm	2006
Hibernation model of tau phosphorylation in hamsters: selective vulnerability of cholinergic basal forebrain neurons - implications for Alzheimer's disease. The European journal of neuroscience, 2007, Volume: 25, Issue:1 Topics: Acetylcholine; Alzheimer Disease; Animals; Blotting, Western; Calcium-Binding Proteins; Choline O-Ac	2007
Properties of glutamate receptors of Alzheimer's disease brain transplanted to frog oocytes. Proceedings of the National Academy of Sciences of the United States of America, 2007, Feb-20, Volume: 104, Issue:8 Topics: Alzheimer Disease; Animals; Anura; Benzothiadiazines; Blotting, Western; Brain Tissue Transplantatio	2007
The alpha7 nicotinic receptor agonist 4OH-GTS-21 protects axotomized septohippocampal cholinergic neurons in wild type but not amyloid-overexpressing transgenic mice. Neuroscience, 2007, Aug-10, Volume: 148, Issue:1 Topics: alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Amyloid; Anabasine; Animals; Axotomy; Ce	2007
Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron, 2007, Sep-06, Volume: 55, Issue:5 Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cognition Disorde	2007
Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron, 2007, Sep-06, Volume: 55, Issue:5 Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cognition Disorde	2007
Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron, 2007, Sep-06, Volume: 55, Issue:5 Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cognition Disorde	2007
Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron, 2007, Sep-06, Volume: 55, Issue:5 Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cognition Disorde	2007
Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron, 2007, Sep-06, Volume: 55, Issue:5 Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cognition Disorde	2007
Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron, 2007, Sep-06, Volume: 55, Issue:5 Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cognition Disorde	2007
Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron, 2007, Sep-06, Volume: 55, Issue:5 Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cognition Disorde	2007
Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron, 2007, Sep-06, Volume: 55, Issue:5 Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cognition Disorde	2007
Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron, 2007, Sep-06, Volume: 55, Issue:5 Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cognition Disorde	2007
Neurotransmitters and CNS disease. Dementia. Lancet (London, England), 1982, Nov-27, Volume: 2, Issue:8309 Topics: Acetylcholine; Aged; Alzheimer Disease; Cerebral Cortex; Choline O-Acetyltransferase; Dementia; Dopa	1982
Neurotransmitters of the cerebral cortex in senile dementia of Alzheimer type. Experimental brain research, 1982, Volume: Suppl 5 Topics: Aged; Alzheimer Disease; Cerebral Cortex; Choline O-Acetyltransferase; Dementia; Enkephalin, Methion	1982
Amino acid release from biopsy samples of temporal neocortex from patients with Alzheimer's disease. Brain research, 1983, Mar-28, Volume: 264, Issue:1 Topics: Acetylcholine; Alzheimer Disease; Amino Acids; Aspartic Acid; Dementia; gamma-Aminobutyric Acid; Glu	1983
Neurochemical characteristics of early and late onset types of Alzheimer's disease. British medical journal (Clinical research ed.), 1984, Mar-31, Volume: 288, Issue:6422 Topics: Age Factors; Aged; Alzheimer Disease; Brain Chemistry; Choline O-Acetyltransferase; gamma-Aminobutyr	1984
Intralaminar neurochemical distributions in human midtemporal cortex: comparison between Alzheimer's disease and the normal. Journal of neurochemistry, 1984, Volume: 42, Issue:5 Topics: Acetylcholinesterase; Alzheimer Disease; Aspartic Acid; Butyrylcholinesterase; Cerebral Cortex; Chol	1984
A preliminary study of free amino acids in the postmortem temporal cortex from Alzheimer-type dementia patients. Neurobiology of aging, 1984,Winter, Volume: 5, Issue:4 Topics: Aged; Alzheimer Disease; Amino Acids; gamma-Aminobutyric Acid; Glutamates; Glutamic Acid; Humans; Ki	1984
Decreased CSF concentrations of homovanillic acid and gamma-aminobutyric acid in Alzheimer's disease. Age- or disease-related modifications? Archives of neurology, 1982, Volume: 39, Issue:11 Topics: Age Factors; Aged; Aging; Alzheimer Disease; Brain Chemistry; Dementia; Female; gamma-Aminobutyric A	1982
Parkinson's disease and benign essential tremor: somatostatin-like immunoreactivity in the cerebrospinal fluid. Advances in neurology, 1984, Volume: 40 Topics: Adult; Aged; Alzheimer Disease; Atrophy; Brain Diseases; Female; gamma-Aminobutyric Acid; Humans; Hu	1984
Striatal dopamine receptors in Alzheimer-type dementia. Neuroscience letters, 1984, Nov-23, Volume: 52, Issue:1-2 Topics: Aged; Alzheimer Disease; Choline O-Acetyltransferase; Dementia; Female; gamma-Aminobutyric Acid; Hom	1984
Gamma-aminobutyric acid and homovanillic acid concentration in the CSF of patients with senile dementia of Alzheimer's type. Archives of neurology, 1984, Volume: 41, Issue:6 Topics: Aged; Alzheimer Disease; Dementia; Female; gamma-Aminobutyric Acid; Homovanillic Acid; Humans; Middl	1984
Correlation of cortical cholinergic and GABA deficits with quantitative neuropathological findings in senile dementia. Brain : a journal of neurology, 1984, Volume: 107 ( Pt 2) Topics: Alzheimer Disease; Brain; Choline O-Acetyltransferase; Cholinergic Fibers; Dementia; gamma-Aminobuty	1984
Potential therapies in aging and senile dementias. Annals of the New York Academy of Sciences, 1982, Volume: 396 Topics: Acetylcholine; Aging; Alzheimer Disease; Animals; Cerebrovascular Circulation; Dementia; gamma-Amino	1982
A post-mortem study of the cholinergic and GABA systems in senile dementia. Brain : a journal of neurology, 1982, Volume: 105, Issue:Pt 2 Topics: Aged; Alzheimer Disease; Brain; Cerebral Cortex; Choline O-Acetyltransferase; Dementia; gamma-Aminob	1982
Hippocampal free amino acids in Alzheimer's disease. Journal of neurochemistry, 1980, Volume: 35, Issue:5 Topics: Aged; Alzheimer Disease; Amino Acids; Arginine; Aspartic Acid; Dementia; gamma-Aminobutyric Acid; Gl	1980
beta-Amyloid peptide fragment 25-35 potentiates the calcium-dependent release of excitatory amino acids from depolarized hippocampal slices. Journal of neuroscience research, 1995, Jul-01, Volume: 41, Issue:4 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Aspartic Acid; Calcium; Excitatory Amino Acids; g	1995
An in vitro 1H nuclear magnetic resonance study of the temporoparietal cortex of Alzheimer brains. Experimental brain research, 1995, Volume: 102, Issue:3 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Creatinine; Female; gamma-Aminobutyric Ac	1995
Inactivity of phosphoethanolamine, an endogenous GABA analog decreased in Alzheimer's disease, at GABA binding sites. Life sciences, 1995, Volume: 56, Issue:26 Topics: Alzheimer Disease; Animals; Ethanolamines; GABA-A Receptor Antagonists; gamma-Aminobutyric Acid; Mal	1995
Parvalbumin-immunoreactive dystrophic neurites and aberrant sprouts in the cerebral cortex of patients with Alzheimer's disease. Neuroscience letters, 1993, Aug-20, Volume: 158, Issue:2 Topics: Aged; Alzheimer Disease; Cerebral Cortex; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged	1993
Cultured GABA-immunoreactive neurons are resistant to toxicity induced by beta-amyloid. Neuroscience, 1993, Volume: 56, Issue:2 Topics: Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Cells, Cultured; Drug Resistance; gamma-Aminob	1993
Cerebrospinal fluid and plasma gamma-aminobutyric acid in Alzheimer's disease. Biological psychiatry, 1996, Nov-01, Volume: 40, Issue:9 Topics: Aged; Alzheimer Disease; Blood-Brain Barrier; Female; gamma-Aminobutyric Acid; Humans; Male; Referen	1996
Gabapentin for behavioral agitation in Alzheimer's disease. Journal of clinical psychopharmacology, 1997, Volume: 17, Issue:1 Topics: Acetates; Aged; Alzheimer Disease; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Admini	1997
Gabapentin in geriatric psychiatry patients. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 1998, Volume: 43, Issue:4 Topics: Acetates; Aged; Aged, 80 and over; Alzheimer Disease; Amines; Anticonvulsants; Bipolar Disorder; Cyc	1998
Bis(7)-tacrine, a novel dimeric AChE inhibitor, is a potent GABA(A) receptor antagonist. Neuroreport, 1999, Mar-17, Volume: 10, Issue:4 Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Electric Stimulation; Electrophysiology; GABA	1999
Interleukin-1beta activates forebrain glial cells and increases nitric oxide production and cortical glutamate and GABA release in vivo: implications for Alzheimer's disease. Neuroscience, 1999, Volume: 91, Issue:3 Topics: Acetylcholine; Alzheimer Disease; Animals; Cerebral Cortex; Extracellular Space; gamma-Aminobutyric	1999
GABA transporters (GAT-1) in Alzheimer's disease. Journal of neural transmission (Vienna, Austria : 1996), 1999, Volume: 106, Issue:11-12 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain Chemistry; Carrier Proteins; Caudate Nucleus; Fema	1999
Treatment of dementia-associated agitation with gabapentin. The Journal of neuropsychiatry and clinical neurosciences, 2000,Winter, Volume: 12, Issue:1 Topics: Acetates; Aged; Aged, 80 and over; Alzheimer Disease; Amines; Anticonvulsants; Cyclohexanecarboxylic	2000
Combination of donepezil and gabapentin for behavioral disorders in Alzheimer's disease. The Journal of clinical psychiatry, 2000, Volume: 61, Issue:1 Topics: Acetates; Aged; Aged, 80 and over; Alzheimer Disease; Amines; Anticonvulsants; Cholinesterase Inhibi	2000
Similar levels of long-term potentiation in amyloid precursor protein -null and wild-type mice in the CA1 region of picrotoxin treated slices. Neuroscience letters, 2000, Jul-07, Volume: 288, Issue:1 Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Central Nervous System Stimulants; Elect	2000
Biochemical and neurobehavioral profile of CHF2819, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease. The Journal of pharmacology and experimental therapeutics, 2000, Volume: 294, Issue:1 Topics: Acetylcholine; Administration, Oral; Alzheimer Disease; Animals; Avoidance Learning; Brain Chemistry	2000
Brain inflammatory reaction in an animal model of neuronal degeneration and its modulation by an anti-inflammatory drug: implication in Alzheimer's disease. The European journal of neuroscience, 2000, Volume: 12, Issue:6 Topics: Acetylcholine; Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Choline O-Acetyl	2000
Neuronal nicotinic receptors in synaptic functions in humans and rats: physiological and clinical relevance. Behavioural brain research, 2000, Volume: 113, Issue:1-2 Topics: Alzheimer Disease; Animals; Brain; Brain Mapping; Cerebral Cortex; Culture Techniques; gamma-Aminobu	2000
Differences between GABA levels in Alzheimer's disease and Down syndrome with Alzheimer-like neuropathology. Naunyn-Schmiedeberg's archives of pharmacology, 2001, Volume: 363, Issue:2 Topics: Adult; Aged; Alzheimer Disease; Amino Acids; Brain; Down Syndrome; Female; gamma-Aminobutyric Acid;	2001
Elevation of AKR7A2 (succinic semialdehyde reductase) in neurodegenerative disease. Brain research, 2001, Oct-19, Volume: 916, Issue:1-2 Topics: Aged; Alzheimer Disease; Animals; Astrocytes; Brain; Cell Compartmentation; Cerebral Cortex; gamma-A	2001
A gamma-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish. EMBO reports, 2002, Volume: 3, Issue:7 Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals; As	2002
Biochemical changes in Alzheimer's disease-senile dementia: neurotransmitters in senile dementia of the Alzheimer's type. Research publications - Association for Research in Nervous and Mental Disease, 1979, Volume: 57 Topics: Acetylcholine; Acetylcholinesterase; Aged; Alzheimer Disease; Brain; Choline O-Acetyltransferase; De	1979
Choline in Alzheimer's disease. Lancet (London, England), 1977, Oct-15, Volume: 2, Issue:8042 Topics: Aged; Alzheimer Disease; Cerebral Cortex; Choline; Choline O-Acetyltransferase; Dementia; gamma-Amin	1977
Cerebrospinal fluid gamma-aminobutyric acid variations in neurological disorders. Archives of neurology, 1977, Volume: 34, Issue:11 Topics: Adolescent; Adult; Aged; Alzheimer Disease; Aminobutyrates; Child; Dementia; gamma-Aminobutyric Acid	1977
The brain in Huntington's chorea. Psychological medicine, 1978, Volume: 8, Issue:3 Topics: Age Factors; Alzheimer Disease; Atrophy; Basal Ganglia; Brain; Cell Survival; Dopamine; gamma-Aminob	1978
Pre- and postsynaptic neurochemical alterations in Alzheimer's disease. Brain research, 1978, Dec-29, Volume: 159, Issue:2 Topics: Aged; Alzheimer Disease; Caudate Nucleus; Choline O-Acetyltransferase; Dementia; Frontal Lobe; gamma	1978
Biochemical aspects of the aging brain. Age and ageing, 1978, Volume: Suppl Topics: Acetylcholine; Aging; Alzheimer Disease; Brain; Cell Count; Dementia; Energy Metabolism; gamma-Amino	1978
Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. The New England journal of medicine, 1992, May-28, Volume: 326, Issue:22 Topics: Aged; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Biological Transport; Brain; Female; gamma-A	1992
[Effects of amiridin and tacrine, drugs effective in Alzheimer's disease, on synaptosomal uptake of neuromediators]. Biulleten' eksperimental'noi biologii i meditsiny, 1992, Volume: 113, Issue:4 Topics: Alzheimer Disease; Aminoquinolines; Animals; Cholinesterase Inhibitors; Dopamine; Epinephrine; gamma	1992
Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms. Neurochemical research, 1992, Volume: 17, Issue:9 Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Biomarkers; Cerebral Cortex; Choline O-Acety	1992
A post-mortem study of noradrenergic, serotonergic and GABAergic neurons in Alzheimer's disease. Journal of the neurological sciences, 1988, Volume: 84, Issue:1 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Choline O-Acetyltransferase; Female; gamma-Aminob	1988
Possible neurotransmitter basis of behavioral changes in Alzheimer's disease. Annals of neurology, 1988, Volume: 23, Issue:6 Topics: Acetylcholine; Aged; Aged, 80 and over; Alzheimer Disease; Cerebral Cortex; gamma-Aminobutyric Acid;	1988
Neuronal loss and GABAergic innervation in the basal forebrain. Trends in neurosciences, 1988, Volume: 11, Issue:5 Topics: Alzheimer Disease; gamma-Aminobutyric Acid; Humans; Neurons	1988
CSF GABA in caregiver spouses of Alzheimer patients. The American journal of psychiatry, 1989, Volume: 146, Issue:6 Topics: Alzheimer Disease; Chromatography, High Pressure Liquid; Dementia; Female; gamma-Aminobutyric Acid;	1989
Loss of cortical GABA uptake sites in Alzheimer's disease. Journal of neural transmission, 1988, Volume: 71, Issue:3 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Binding, Competitive; Cerebral Cortex; gamma-Aminobutyri	1988
[Ageing and neurotransmitters]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1985, Volume: 74, Issue:10 Topics: Acetylcholine; Aged; Aging; Alzheimer Disease; Animals; Brain; Choline O-Acetyltransferase; Dopamine	1985
Regional distribution of amino acid transmitters in postmortem brains of presenile and senile dementia of Alzheimer type. Annals of neurology, 1986, Volume: 19, Issue:3 Topics: Aged; Aging; Alzheimer Disease; Aspartic Acid; Female; gamma-Aminobutyric Acid; Glutamates; Glutamic	1986
Significance of neurotransmitter abnormalities in Alzheimer's disease. Research publications - Association for Research in Nervous and Mental Disease, 1986, Volume: 64 Topics: Alzheimer Disease; Brain; Brain Chemistry; Cerebral Cortex; Cholecystokinin; Choline O-Acetyltransfe	1986
A postmortem study of amino acid neurotransmitters in Alzheimer's disease. Annals of neurology, 1986, Volume: 20, Issue:5 Topics: Aged; Aging; Alanine; Alzheimer Disease; Amino Acids; Aspartic Acid; Brain; gamma-Aminobutyric Acid;	1986
Diazepam-binding inhibitor. A brain neuropeptide present in human spinal fluid: studies in depression, schizophrenia, and Alzheimer's disease. Archives of general psychiatry, 1986, Volume: 43, Issue:12 Topics: Adult; Age Factors; Aged; Alzheimer Disease; Depressive Disorder; Diazepam Binding Inhibitor; Female	1986
[Drug therapy of Alzheimer's disease. General concepts on nootropic drugs]. Nihon rinsho. Japanese journal of clinical medicine, 1988, Volume: 46, Issue:7 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amantadine; Aminoacridines; Dementia; gamma-Aminobutyric	1988
[Therapeutic application of cerebral metabolism enhancers to Alzheimer's disease and their limitations]. Nihon rinsho. Japanese journal of clinical medicine, 1988, Volume: 46, Issue:7 Topics: Alzheimer Disease; Brain; Energy Metabolism; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Oxy	1988
Gamma-aminobutyric acid concentration in brain tissue at two stages of Alzheimer's disease. Brain : a journal of neurology, 1988, Volume: 111 ( Pt 4) Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain Chemistry; Cerebral Cortex; Choline O-Acetyltransf	1988
Amino acids, glutathione, and glutathione transferase activity in the brains of patients with Alzheimer's disease. Annals of neurology, 1987, Volume: 21, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Amino Acids; Brain; gamma-Aminobutyri	1987
The "antidementia drug" pantoyl-gamma-aminobutyric acid increases high affinity uptake of choline by slices of rat brain. Neuropharmacology, 1986, Volume: 25, Issue:3 Topics: Alzheimer Disease; Animals; Brain; Calcium; Cerebral Cortex; Choline; Corpus Striatum; gamma-Aminobu	1986
A disorder of cortical GABAergic innervation in Alzheimer's disease. Neuroscience letters, 1987, Jan-14, Volume: 73, Issue:2 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebral Cortex; Female; gamma-Aminobutyric Acid; Hippoc	1987
Changes in cerebrospinal fluid associated with dementia. Annals of the New York Academy of Sciences, 1985, Volume: 444 Topics: Alzheimer Disease; Catecholamines; gamma-Aminobutyric Acid; Humans; Peptides; Prognosis; Serotonin	1985